HUM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

32.07B

+9.77%

-3.993

+84.84%

35.44B

+10.38%

10.644

-8.08%

36.27B

+11.97%

5.344

-14.77%

Estimates Revision

The market is revising Upward the revenue expectations for Humana Inc. (HUM) for FY2025, with the revenue forecasts being adjusted by 0.65% over the past three months. During the same period, the stock price has changed by -4.73%.

Revenue Estimates for FY2025

Revise Upward

+0.65%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.08%

In Past 3 Month

Stock Price

Go Down

-4.73%

In Past 3 Month

18 Analyst Rating

Wall Street analysts forecast HUM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUM is 293.81 USD with a low forecast of 231.00 USD and a high forecast of 341.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

9 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

231.00

Averages

293.81

High

341.00

Current: 0.000

Low

231.00

Averages

293.81

High

341.00

Wells Fargo

Overweight -> Equal Weight

downgrade

$290

2026-01-07

New

Reason

Wells Fargo

Price Target

$290

2026-01-07

New

downgrade

Overweight -> Equal Weight

Reason

Wells Fargo downgraded Humana to Equal Weight from Overweight with a $290 price target.

Wells Fargo

Stephen Baxter

Overweight -> Equal Weight

downgrade

$290

2026-01-07

New

Reason

Wells Fargo

Stephen Baxter

Price Target

$290

2026-01-07

New

downgrade

Overweight -> Equal Weight

Reason

As previously reported, Wells Fargo analyst Stephen Baxter downgraded Humana to Equal Weight from Overweight with a $290 price target. For managed care organizations, the firm is most constructive on Medicare Advantage with uncertainty high for Medicaid/Exchanges. Wells sees a more difficult backdrop for hospitals in 2026 as post-COVID tailwinds wane and legislative risks near. Distributor debate remains revisions vs. multiples. Regarding Humana, the firm is more cautious on achievability of the company's margin objective in 2026 given lack of benefit cuts.

Bernstein

Outperform

maintain

$341 -> $344

2026-01-06

New

Reason

Bernstein

Price Target

$341 -> $344

2026-01-06

New

maintain

Outperform

Reason

Bernstein raised the firm's price target on Humana to $344 from $341 and keeps an Outperform rating on the shares. The firm sees a sector turnaround in the government managed care organization sector beginning in 2026, but expects to see bumps in the recovery. Bernstein believes all MCO sectors present attractive entry points, with Medicare Advantage likely to see the nearest term earnings improvements and Medicaid representing the most attractive valuations.

Barclays

Equal Weight

maintain

$234 -> $245

2026-01-05

New

Reason

Barclays

Price Target

$234 -> $245

2026-01-05

New

maintain

Equal Weight

Reason

Barclays raised the firm's price target on Humana to $245 from $234 and keeps an Equal Weight rating on the shares. The firm sees managed care stocks benefiting in 2026 from the prospects of margin expansion and rotation away from artificial intelligence-related stocks toward "de-rated underperformers."

Morgan Stanley

Erin Wright

Equal Weight

downgrade

$277 -> $262

2025-12-18

Reason

Morgan Stanley

Erin Wright

Price Target

$277 -> $262

2025-12-18

downgrade

Equal Weight

Reason

Morgan Stanley analyst Erin Wright lowered the firm's price target on Humana to $262 from $277 and keeps an Equal Weight rating on the shares. For healthcare technology and providers, the firm sees an "attractive backdrop for alpha-generation opportunities" in 2026, the analyst tells investors. Meanwhile, managed care stocks have underperformed in 2025 and are facing "another year of unprecedented policy, reimbursement, and utilization headwinds," the analyst added in a year-ahead outlook note for the Healthcare Services group.

Argus

Hold

maintain

2025-12-08

Reason

Argus

Price Target

2025-12-08

maintain

Hold

Reason

Argus keeps a Hold rating on Humana but notes that the company is focused on recovering EPS growth in 2027 and beyond, adding that should the firm see signs of sustained profitability, it would re-consider a Buy rating on the name. Argus further states that while Humana is managing the rising medical cost trends, these actions may slow Medicare Advantage growth in the near-term and slow EPS growth, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Humana Inc (HUM.N) is 19.64, compared to its 5-year average forward P/E of 18.62. For a more detailed relative valuation and DCF analysis to assess Humana Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

18.62

Current PE

19.64

Overvalued PE

20.86

Undervalued PE

16.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.90

Current EV/EBITDA

11.44

Overvalued EV/EBITDA

13.46

Undervalued EV/EBITDA

10.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.48

Current PS

0.23

Overvalued PS

0.65

Undervalued PS

0.32

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

HUM News & Events

Events Timeline

No data

News

9.5

01-09Newsfilter

PinnedHumana to Release 4Q25 Financial Results on February 11, 2026

9.5

01-09Businesswire

Humana to Release 4Q25 Financial Results on February 11, 2026

8.0

01-09Benzinga

U.S. House Passes Bill Extending ACA Subsidies, Impacting 22 Million Americans

People Also Watch

Frequently Asked Questions

What is Humana Inc (HUM) stock price today?

The current price of HUM is 276.85 USD — it has decreased -0.26 % in the last trading day.

What is Humana Inc (HUM)'s business?

Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.

What is the price predicton of HUM Stock?

What is Humana Inc (HUM)'s revenue for the last quarter?

Humana Inc revenue for the last quarter amounts to 32.65B USD, increased 11.06 % YoY.

What is Humana Inc (HUM)'s earnings per share (EPS) for the last quarter?

Humana Inc. EPS for the last quarter amounts to 1.61 USD, decreased -59.45 % YoY.

What changes have occurred in the market's expectations for Humana Inc (HUM)'s fundamentals?

How many employees does Humana Inc (HUM). have?

Humana Inc (HUM) has 65680 emplpoyees as of January 10 2026.

What is Humana Inc (HUM) market cap?

Today HUM has the market capitalization of 33.30B USD.